Next Capital Management’s Pacira BioSciences PCRX Stock Holding History

Next Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,503	Closed	-$204K	–	117
2022 Q2	$204K	Buy	3,503 +3	+0.1%	+$197	0.15%	105
2022 Q1	$267K	Hold	3,500	–	–	0.18%	95
2021 Q4	$211K	Buy	+3,500	New	+$193K	0.14%	100
2021 Q3	–	Sell	-3,500	Closed	-$212K	–	111
2021 Q2	$212K	Hold	3,500	–	–	0.14%	103
2021 Q1	$245K	Hold	3,500	–	–	0.16%	97
2020 Q4	$209K	Buy	+3,500	New	+$205K	0.15%	99

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Next Capital Management's PCRX Position: Q3 2022 in Review

Next Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2022, closing a stake of 3,503 shares — an estimated $204K sold.

Next Capital Management first reported a position in PCRX in Q4 2020 and held it in 6 quarters. The position peaked at $267K in Q1 2022. 273 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.

Next Capital Management reported no remaining Pacira BioSciences position as of Q3 2022 after selling out during the quarter.
Next Capital Management sold 3,503 Pacira BioSciences shares in Q3 2022, an estimated $204K.
Next Capital Management first reported a position in Pacira BioSciences in Q4 2020 and held it in 6 quarters.
Next Capital Management's Pacira BioSciences position peaked at $267K in Q1 2022.
273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.

Based on Next Capital Management's 13F filing for Q3 2022, filed 14 Oct 2022.